Taiwan Bio Therapeutics Co., Ltd
Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei City, Taiwan.
Taiwan Bio Therapeutics Co., Ltd (6892) - Total Liabilities
Latest total liabilities as of June 2025: NT$391.88 Million TWD
Based on the latest financial reports, Taiwan Bio Therapeutics Co., Ltd (6892) has total liabilities worth NT$391.88 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Taiwan Bio Therapeutics Co., Ltd - Total Liabilities Trend (2020–2024)
This chart illustrates how Taiwan Bio Therapeutics Co., Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Taiwan Bio Therapeutics Co., Ltd Competitors by Total Liabilities
The table below lists competitors of Taiwan Bio Therapeutics Co., Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yield10 Bioscience Inc
NASDAQ:YTEN
|
USA | $9.21 Million |
|
Fingerprint Cards AB (publ)
OTCGREY:FGRRF
|
USA | $54.60 Million |
|
United Royale Holdings Corp
OTCQB:URYL
|
USA | $44.13K |
|
Alternative Investment Trust
AU:AIQ
|
Australia | AU$261.00K |
|
AUST AGRICULTURAL
MU:AY5
|
Germany | €847.57 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Taiwan Bio Therapeutics Co., Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Taiwan Bio Therapeutics Co., Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Taiwan Bio Therapeutics Co., Ltd (2020–2024)
The table below shows the annual total liabilities of Taiwan Bio Therapeutics Co., Ltd from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$380.58 Million | +15.87% |
| 2023-12-31 | NT$328.47 Million | -4.56% |
| 2022-12-31 | NT$344.18 Million | +3.16% |
| 2021-12-31 | NT$333.63 Million | +151.89% |
| 2020-12-31 | NT$132.45 Million | -- |